Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923284 · ClinicalTrials.gov registry record
NANOTECH RCC Biomarkers
A clinical trial of Renal Cell Carcinoma and Renal Cell Cancer, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 407
- Enrollment target
- 1
- Study location
NCT02923284: Completed study of Renal Cell Carcinoma and Renal Cell Cancer, sponsored by Washington University School of Medicine.
NCT02923284 is a study of Renal Cell Carcinoma and Renal Cell Cancer that has completed, run by Washington University School of Medicine. The registered enrollment target is 407 participants, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923284, a study of Renal Cell Carcinoma and Renal Cell Cancer, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 407 participants
- Enrollment target
- 1
- Study location
Study Summary
The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules \[biomarkers\] of RCC that can be used to develop a reliable low-cost screening method at the point of service. If successful, our method would provide a diagnostic test to distinguish benign kidney masses from malignant ones, eliminating the need to surgically remove a kidney with a benign tumor.
Primary Outcome
Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
Conditions Studied
Study Locations (1)
Missouri
- Washington University St Louis School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-01-02 |
What the finished NCT02923284 record still lists
NCT02923284 is an observational study that tracks outcomes without assigning an intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (70% higher).
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT02923284 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02923284 about?
NCT02923284 is a clinical study titled "NANOTECH RCC Biomarkers". The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules...
What is the current status of trial NCT02923284?
This trial is currently completed. The enrollment target is 407 participants. The study started on 2016-08. Estimated completion is 2020-01-02.
What conditions does trial NCT02923284 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Renal Cell Cancer.
Who is sponsoring clinical trial NCT02923284?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02923284 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02923284's enrollment target sits among peer trials
407 21st of 121 higher than 101 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
- NCT07094516 · 407 participants · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia